Development of major depressive disorder during smoking-cessation treatment

Belinda Borrelli, Raymond Niaura, Nancy J. Keuthen, Michael G. Goldstein, Judith D. DePue, Chris Murphy, David Abrams

Research output: Contribution to journalArticle

Abstract

Background: Several studies have shown an association between smoking and major depressive disorder (MDD), but few have prospectively examined subjects who develop MDD after quitting smoking. This descriptive study evaluated the development of MDD after smoking cessation, as assessed by a structured clinical interview at both baseline and the end of treatment. Method: Nondepressed participants (N = 114) in a trial investigating the effect of fluoxetine on smoking cessation were administered the Structured Clinical Interview for DSM-III-R at baseline ad posttreatment to evaluate the impact of quitting smoking on the development of MDD. Depressive symptoms were additionally assessed with the Beck Depression Inventory and the Hamilton Rating Scale for Depression. Results: At baseline, 32% of the subjects reported a history of MDD. Sixty-nine subjects completed the SCID at baseline and posttreatment. At posttreatment, 5 subjects (7%) met threshold criteria for MDD; one were taking the highest dose of fluoxetine (60 mg), 4 were taking 30 mg, and 1 was taking placebo. All 5 had a history of MDD; 3 were women. Four had a history of substance abuse and attained at least 3 consecutive biochemically verified weeks of smoking abstinence. Those who developed MDD after treatment scored significantly higher on measures of depressed mood at baseline than those who did not develop MDD after smoking- cessation treatment. Conclusion: The results from this descriptive study suggest that a subset of smokers may be at risk for developing MDD after smoking cessation.

Original languageEnglish (US)
Pages (from-to)534-538
Number of pages5
JournalJournal of Clinical Psychiatry
Volume57
Issue number11
StatePublished - Nov 1996

Fingerprint

Withholding Treatment
Major Depressive Disorder
Smoking Cessation
Smoking
Fluoxetine
Depression
Interviews
Diagnostic and Statistical Manual of Mental Disorders
Substance-Related Disorders
Placebos
Equipment and Supplies

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Borrelli, B., Niaura, R., Keuthen, N. J., Goldstein, M. G., DePue, J. D., Murphy, C., & Abrams, D. (1996). Development of major depressive disorder during smoking-cessation treatment. Journal of Clinical Psychiatry, 57(11), 534-538.

Development of major depressive disorder during smoking-cessation treatment. / Borrelli, Belinda; Niaura, Raymond; Keuthen, Nancy J.; Goldstein, Michael G.; DePue, Judith D.; Murphy, Chris; Abrams, David.

In: Journal of Clinical Psychiatry, Vol. 57, No. 11, 11.1996, p. 534-538.

Research output: Contribution to journalArticle

Borrelli, B, Niaura, R, Keuthen, NJ, Goldstein, MG, DePue, JD, Murphy, C & Abrams, D 1996, 'Development of major depressive disorder during smoking-cessation treatment', Journal of Clinical Psychiatry, vol. 57, no. 11, pp. 534-538.
Borrelli B, Niaura R, Keuthen NJ, Goldstein MG, DePue JD, Murphy C et al. Development of major depressive disorder during smoking-cessation treatment. Journal of Clinical Psychiatry. 1996 Nov;57(11):534-538.
Borrelli, Belinda ; Niaura, Raymond ; Keuthen, Nancy J. ; Goldstein, Michael G. ; DePue, Judith D. ; Murphy, Chris ; Abrams, David. / Development of major depressive disorder during smoking-cessation treatment. In: Journal of Clinical Psychiatry. 1996 ; Vol. 57, No. 11. pp. 534-538.
@article{0dc2f100ad284f55ba110007b2a14a97,
title = "Development of major depressive disorder during smoking-cessation treatment",
abstract = "Background: Several studies have shown an association between smoking and major depressive disorder (MDD), but few have prospectively examined subjects who develop MDD after quitting smoking. This descriptive study evaluated the development of MDD after smoking cessation, as assessed by a structured clinical interview at both baseline and the end of treatment. Method: Nondepressed participants (N = 114) in a trial investigating the effect of fluoxetine on smoking cessation were administered the Structured Clinical Interview for DSM-III-R at baseline ad posttreatment to evaluate the impact of quitting smoking on the development of MDD. Depressive symptoms were additionally assessed with the Beck Depression Inventory and the Hamilton Rating Scale for Depression. Results: At baseline, 32{\%} of the subjects reported a history of MDD. Sixty-nine subjects completed the SCID at baseline and posttreatment. At posttreatment, 5 subjects (7{\%}) met threshold criteria for MDD; one were taking the highest dose of fluoxetine (60 mg), 4 were taking 30 mg, and 1 was taking placebo. All 5 had a history of MDD; 3 were women. Four had a history of substance abuse and attained at least 3 consecutive biochemically verified weeks of smoking abstinence. Those who developed MDD after treatment scored significantly higher on measures of depressed mood at baseline than those who did not develop MDD after smoking- cessation treatment. Conclusion: The results from this descriptive study suggest that a subset of smokers may be at risk for developing MDD after smoking cessation.",
author = "Belinda Borrelli and Raymond Niaura and Keuthen, {Nancy J.} and Goldstein, {Michael G.} and DePue, {Judith D.} and Chris Murphy and David Abrams",
year = "1996",
month = "11",
language = "English (US)",
volume = "57",
pages = "534--538",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "11",

}

TY - JOUR

T1 - Development of major depressive disorder during smoking-cessation treatment

AU - Borrelli, Belinda

AU - Niaura, Raymond

AU - Keuthen, Nancy J.

AU - Goldstein, Michael G.

AU - DePue, Judith D.

AU - Murphy, Chris

AU - Abrams, David

PY - 1996/11

Y1 - 1996/11

N2 - Background: Several studies have shown an association between smoking and major depressive disorder (MDD), but few have prospectively examined subjects who develop MDD after quitting smoking. This descriptive study evaluated the development of MDD after smoking cessation, as assessed by a structured clinical interview at both baseline and the end of treatment. Method: Nondepressed participants (N = 114) in a trial investigating the effect of fluoxetine on smoking cessation were administered the Structured Clinical Interview for DSM-III-R at baseline ad posttreatment to evaluate the impact of quitting smoking on the development of MDD. Depressive symptoms were additionally assessed with the Beck Depression Inventory and the Hamilton Rating Scale for Depression. Results: At baseline, 32% of the subjects reported a history of MDD. Sixty-nine subjects completed the SCID at baseline and posttreatment. At posttreatment, 5 subjects (7%) met threshold criteria for MDD; one were taking the highest dose of fluoxetine (60 mg), 4 were taking 30 mg, and 1 was taking placebo. All 5 had a history of MDD; 3 were women. Four had a history of substance abuse and attained at least 3 consecutive biochemically verified weeks of smoking abstinence. Those who developed MDD after treatment scored significantly higher on measures of depressed mood at baseline than those who did not develop MDD after smoking- cessation treatment. Conclusion: The results from this descriptive study suggest that a subset of smokers may be at risk for developing MDD after smoking cessation.

AB - Background: Several studies have shown an association between smoking and major depressive disorder (MDD), but few have prospectively examined subjects who develop MDD after quitting smoking. This descriptive study evaluated the development of MDD after smoking cessation, as assessed by a structured clinical interview at both baseline and the end of treatment. Method: Nondepressed participants (N = 114) in a trial investigating the effect of fluoxetine on smoking cessation were administered the Structured Clinical Interview for DSM-III-R at baseline ad posttreatment to evaluate the impact of quitting smoking on the development of MDD. Depressive symptoms were additionally assessed with the Beck Depression Inventory and the Hamilton Rating Scale for Depression. Results: At baseline, 32% of the subjects reported a history of MDD. Sixty-nine subjects completed the SCID at baseline and posttreatment. At posttreatment, 5 subjects (7%) met threshold criteria for MDD; one were taking the highest dose of fluoxetine (60 mg), 4 were taking 30 mg, and 1 was taking placebo. All 5 had a history of MDD; 3 were women. Four had a history of substance abuse and attained at least 3 consecutive biochemically verified weeks of smoking abstinence. Those who developed MDD after treatment scored significantly higher on measures of depressed mood at baseline than those who did not develop MDD after smoking- cessation treatment. Conclusion: The results from this descriptive study suggest that a subset of smokers may be at risk for developing MDD after smoking cessation.

UR - http://www.scopus.com/inward/record.url?scp=0029829424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029829424&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 534

EP - 538

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 11

ER -